Free accessResearch articleFirst published online 2002-09
Breast Enhanced Scintigraphy Testing Distinguishes Between Normal,Inflammatory Breast Changes,and Breast Cancer: A Prospective Analysis and Comparison With Mammography
The detection of breast cancer has primarily focused on anatomic findings, whereas assessment of physiologic information using nuclear imaging has been used for the detection of heart disease. Using this approach, the authors developed a method (breast enhanced scintigraphy test [BEST]) for differentiation of breast tissue by enhancing the delivery of isotope. To determine if this technique could distinguish between normal (Nl), inflammatory changes of the breast (ICB), and breast cancer (CA), 100 women were prospectively studied using BEST imaging, and results were compared with mammography and pathology findings using either biopsy or ductoscopy approaches. Mammography demonstrated a sensitivity and specificity of 69% and 84%, respectively. Using BEST imaging, maximal count activity (MCA) was able to distinguishbetween Nl, ICB, and CA. The results of 2-tailedttest analysis demonstrated statistically significant differences between Nl and ICB MCA (P ≤ .001); ICB and CA MCA (P ≤ .001); and N1 and CA MCA (P ≤ .001). Using MCA results obtained via BEST imaging, breast tissue was able to be differentiated, whereas mammography was able to detect breast cancer in only 69% of cases and incorrectly identified cancer in 16% of cases.
References
1.
American Heart Association. Heart and Stroke Statistical Update. American Heart Association; 1998.
2.
The Health Network. Retrieved November 16, 1999, from http://www.thehealthnetwork.com
3.
Burman ML, Taplin SH, Herta DF, Elmore JG.Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization. Ann Intern Med. 1999;131: 1-6.
4.
Fletcher SW.False-positive screening mammograms: good news, but more to do. Ann Intern Med. 1999;131:60-61.
5.
Christiansen CL, Wang F, Barton MB, et al.Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst. 200;92:1657-1666.
6.
Rissanen TJ, Makarainen HP, Mattila SI, Lindholm EL, Heikkinen MI, Kiviniemi HO.Breast cancer recurrence after mastectomy: diagnosis with mammography and US. Radiology. 1993;188:463-467.
7.
Eary JF.Nuclear medicine in cancer diagnosis. Lancet. 1999;354:853-857.
8.
He J, Li Y, Su J.Differentiation of benign and malignant palpable breast masses using 99m Tc-MIBI imaging. Hunan I Ko Ta Hsueh Hsueh Pao. 1997;22:226-228.
9.
Palmedo H, Biersack HJ, Lastoria S, et al.Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med. 1998;25:375-385.
10.
Tilling R, Tatsch K, Sommer H, et al.Technetium-99msestamibi scintimammography for the detection of breast carcinoma: comparison between planar and SPECT imaging. J Nucl Med. 1998;39:849-856.
11.
Salvatore M, Del Vecchio S.Dynamic imaging: scintimammography. Eur J Radiol. 1998;27:S259-S264.
12.
Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ.Scintigraphic imaging of breast cancer: a review. Nucl Med Commun. 1997;18:698-709.
13.
Cwikla JB, Buscombe JR, Barlow RV, et al.The effect of chemo-therapy on the uptake of technetium-99m sestamibi in breast cancer. Eur J Nucl Med. 1997;24:1175-1178.
14.
Cwikla JB, Buscombe JR, Kelleher SM, et al.Comparison of accuracy of scintimammography and X-ray mammography in the diagnosis of primary breast cancer in patients selected for surgical biopsy. Clin Radiol. 1998;53:274-280.
15.
Amano S, Inoue T, Tomiyoshi K, Ando T, Endo K.In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med. 1998;39:1424-1427.
16.
Bombardieri E, Crippa F, Maffioli L, et al.Nuclear medicine approaches for detection of axillary lymph node metastasis. QJ Nucl Med. 1998;42(1):54-65.
17.
Gulec SA, Moffat FL, Carroll RG, Krag DN.Gamma probe guided sentinel node biopsy in breast cancer. Q J Nucl Med. 1997;41:251-261.
18.
Taillefer R, Robidoux A, Turpin S, Lambert R, Cantin J, Leveille J.Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. J Nucl Med. 1998;39:459-464.
19.
Fleming RM, Dooley WC, Boyd LB, Kubovy K.Breast enhanced scintigraphy testing (BEST)—increased accuracy in detecting breast cancer accomplished by combining breast and cardiac imaging. Paper presented at:48th Annual Scientific Session of the Society of Nuclear Medicine; June 27, 2001; Toronto, Ontario, Canada.
20.
Fleming RM, Boyd L, Forster M.Angina is caused by regional blood flow differences—proof of a physiologic (not anatomic) narrowing. Paper presented at: Joint Session of the European Society-American College of Cardiology, ACC 49th Annual Scientific Sessions; March 12, 2000; Anaheim, CA.
21.
Fleming RM.Regional blood flow differences induced by high dose dipyridamole explain etiology of angina. Paper presented at:3rd International College of Coronary Artery Dis ease From Prevention to Intervention; October 4, 2000; Lyon, France.
22.
Fleming RM.Nuclear cardiology: its role in the detection and management of coronary artery disease. In: Chang JC, ed. Textbook of Angiology. New York, NY: Springer-Verlag; 1999:397-406.
23.
Dooley WC.Endoscopic visualization of breast tumors. JAMA. 2000;284:1518.
24.
Screening for breast cancer. Harvard Medical School Consumer Health Information. Retrieved February 27, 2001, from http://www.intelihealth.com.
25.
Fleming RM, Boyd LB, Kubovy C.Myocardial perfusion imaging using high dose dipyridamole defines angina: the difference between coronary artery disease (CAD) and coronary lumen disease (CLD). Paper presented at:48th Annual Scientific Session of the Society of Nuclear Medicine; June 27, 2001; Toronto, Ontario, Canada.
26.
Fleming RM, Dooley WC, Boyd LB, Kubovy C.Breast enhanced scintigraphy testing (BEST)—increased accuracy in detecting breast cancer accomplished by combining breast and cardiac imaging. Paper presented at:48th Annual Scientific Session of the Society of Nuclear Medicine; June 26, 2001; Toronto, Ontario, Canada.
27.
Fleming RM.The pathogenesis of vascular disease. In: Chang JC, ed. Textbook of Angiology. New York, NY: Springer-Verlag; 1999:787-798.
28.
Folkman J, Merler E, Abernathy C, Williams G.Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133:275-288.
29.
Stewart RJ, Panigraphy D, Flynn E, Folkman J.Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol. 2001;165:688-693.
